Eupraxia Pharmaceuticals (NASDAQ:EPRX) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research downgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) from a hold rating to a strong sell rating in a research report released on Tuesday morning,Zacks.com reports.

A number of other brokerages also recently issued reports on EPRX. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. HC Wainwright reduced their price objective on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, Cantor Fitzgerald increased their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Stock Performance

EPRX stock opened at $7.51 on Tuesday. The firm’s fifty day moving average is $8.30 and its 200 day moving average is $6.87. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $9.32. The firm has a market cap of $270.06 million, a P/E ratio of -7.29 and a beta of 1.27.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). As a group, analysts forecast that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth $122,000. Ikarian Capital LLC purchased a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter worth approximately $4,606,000. Squadron Capital Management LLC purchased a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter worth $3,775,000. SummitTX Capital L.P. purchased a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth about $1,328,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter worth approximately $326,000.

More Eupraxia Pharmaceuticals News

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $11.00 price target on EPRX, signaling continued broker conviction and implying meaningful upside from current levels. Read More.
• Positive Sentiment: Lifesci Capital kept a “Strong-Buy” rating even as it adjusted estimates, which supports continued institutional optimism about the company’s longer-term prospects. Read More.
• Neutral Sentiment: HC Wainwright published a detailed multi-year forecast schedule (quarterly 2026 estimates and longer-term FY2030 view), providing updated guidance investors can use to re-model cash needs and valuation. Read More.
• Negative Sentiment: HC Wainwright cut near- and medium-term EPS estimates sharply: FY2026 from ($0.52) to ($0.96), FY2027 to ($0.91) (from $0.55 prior), FY2028 to ($1.05) (from ($0.63)), and FY2029 to ($0.42) (from ($0.13)). Those downgrades increase short-term downside risk and reflect a worse-than-expected path to profitability. Read More.
• Negative Sentiment: HC Wainwright trimmed its prior $12 price target to $11 (still a buy), signaling a modest reduction in their valuation uplift for the stock. Read More.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.